Statin Not Effective for Children With Learning Disabilities Caused by Neurofibromatosis
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Statin Not Effective for Children With Learning Disabilities Caused by Neurofibromatosis

CHICAGO -- July 15, 2008 -- Use of simvastatin in children with neurofibromatosis type 1 (NF1) did not result in improved cognitive function, according to a study in the July 16 issue of JAMA.

Lianne C. Krab, Erasmus MC University Medical Center and Sophia Children's Hospital, Rotterdam, Netherlands, and colleagues, conducted a randomised trial to study the effect of the simvastatin on cognitive function.

The study included a total of 62 children with NF1. The children received simvastatin or placebo treatment once daily for 12 weeks.

After the treatment period, there was no significant difference between the simvastatin and placebo groups on several cognitive measures, including assessing nonverbal long-term memory, and assessing attention and prism adaptation task.

In the secondary outcome measures, researchers found a significant improvement in object assembly scores in the simvastatin group, which was specifically observed in children with poor baseline performance. Other secondary outcome measures, such as attention fluctuations and a developmental test of visual-motor integration revealed no significant effect of simvastatin treatment.

"The negative outcome of this trial suggests that simvastatin should not be prescribed to ameliorate the cognitive deficits associated with NF1. Further studies to evaluate a longer treatment period and whether the object assembly finding is spurious may be warranted," the authors wrote.

SOURCE: JAMA

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities